3 out of 10 children will experience relapse after completion of upfront therapy
Despite completing a lengthy and aggressive standard of care regimen for high-risk neuroblastoma, your child may still be at risk for relapse.
- Relapse risk is higher in the first few years after achieving remission
- Rates of overall survival significantly worsen with relapse
- A return to active disease further exposes a child to aggressive treatments
Maintenance therapy could offer an additional layer of protection against relapse
The addition of maintenance therapy following upfront treatment may help to maintain your child’s response, decrease the chance of relapse, and improve their overall chance of survival.
